ID   ALG9_HUMAN              Reviewed;         611 AA.
AC   Q9H6U8; Q6ZMD5; Q7Z4R4; Q96GS7; Q96PB9; Q9H068;
DT   30-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   30-AUG-2005, sequence version 2.
DT   10-MAY-2017, entry version 133.
DE   RecName: Full=Alpha-1,2-mannosyltransferase ALG9 {ECO:0000305};
DE            EC=2.4.1.259 {ECO:0000269|PubMed:15148656, ECO:0000269|PubMed:15945070};
DE            EC=2.4.1.261 {ECO:0000269|PubMed:15148656, ECO:0000269|PubMed:15945070};
DE   AltName: Full=Asparagine-linked glycosylation protein 9 homolog {ECO:0000312|HGNC:HGNC:15672};
DE   AltName: Full=Disrupted in bipolar disorder protein 1 {ECO:0000303|PubMed:12030331};
DE   AltName: Full=Dol-P-Man:Man(6)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferase {ECO:0000305};
DE   AltName: Full=Dol-P-Man:Man(8)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferase {ECO:0000305};
GN   Name=ALG9 {ECO:0000312|HGNC:HGNC:15672};
GN   Synonyms=DIBD1 {ECO:0000303|PubMed:12030331};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CHROMOSOMAL TRANSLOCATION,
RP   TISSUE SPECIFICITY, AND VARIANTS ILE-289 AND LEU-506.
RX   PubMed=12030331; DOI=10.1007/s10048-001-0129-x;
RA   Baysal B.E., Willett-Brozick J.E., Badner J.A., Corona W.,
RA   Ferrell R.E., Nimgaonkar V.L., Detera-Wadleigh S.D.;
RT   "A mannosyltransferase gene at 11q23 is disrupted by a translocation
RT   breakpoint that co-segregates with bipolar affective disorder in a
RT   small family.";
RL   Neurogenetics 4:43-53(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Lymphoma;
RA   Guo J.H., Yu L.;
RL   Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Uterus;
RX   PubMed=11230166; DOI=10.1101/gr.GR1547R;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H.,
RA   Lauber J., Duesterhoeft A., Beyer A., Koehrer K., Strack N.,
RA   Mewes H.-W., Ottenwaelder B., Obermaier B., Tampe J., Heubner D.,
RA   Wambutt R., Korn B., Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and
RT   analysis of 500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4), AND VARIANT
RP   ILE-289.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, PATHWAY, SUBCELLULAR LOCATION, VARIANT
RP   CDG1L LYS-523, AND VARIANT ILE-289.
RX   PubMed=15148656; DOI=10.1086/422367;
RA   Frank C.G., Grubenmann C.E., Eyaid W., Berger E.G., Aebi M.,
RA   Hennet T.;
RT   "Identification and functional analysis of a defect in the human ALG9
RT   gene: definition of congenital disorder of glycosylation type IL.";
RL   Am. J. Hum. Genet. 75:146-150(2004).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND VARIANT CDG1L CYS-287.
RX   PubMed=15945070; DOI=10.1002/ajmg.a.30851;
RA   Weinstein M., Schollen E., Matthijs G., Neupert C., Hennet T.,
RA   Grubenmann C.E., Frank C.G., Aebi M., Clarke J.T.R., Griffiths A.,
RA   Seargeant L., Poplawski N.;
RT   "CDG-IL: an infant with a novel mutation in the ALG9 gene and
RT   additional phenotypic features.";
RL   Am. J. Med. Genet. A 136:194-197(2005).
RN   [8]
RP   LACK OF ASSOCIATION WITH BIPOLAR AFFECTIVE DISORDERS.
RX   PubMed=16859551; DOI=10.1186/1744-9081-2-25;
RA   Baysal B.E., Willett-Brozick J.E., Bacanu S.A., Detera-Wadleigh S.,
RA   Nimgaonkar V.L.;
RT   "Common variations in ALG9 are not associated with bipolar I disorder:
RT   a family-based study.";
RL   Behav. Brain Funct. 2:25-25(2006).
RN   [9]
RP   INVOLVEMENT IN GIKANIS.
RX   PubMed=25966638; DOI=10.1038/ejhg.2015.91;
RA   Tham E., Eklund E.A., Hammarsjoe A., Bengtson P., Geiberger S.,
RA   Lagerstedt-Robinson K., Malmgren H., Nilsson D., Grigelionis G.,
RA   Conner P., Lindgren P., Lindstrand A., Wedell A., Albaage M.,
RA   Zielinska K., Nordgren A., Papadogiannakis N., Nishimura G.,
RA   Grigelioniene G.;
RT   "A novel phenotype in N-glycosylation disorders: Gillessen-Kaesbach-
RT   Nishimura skeletal dysplasia due to pathogenic variants in ALG9.";
RL   Eur. J. Hum. Genet. 24:198-207(2016).
CC   -!- FUNCTION: Catalyzes the transfer of mannose from Dol-P-Man to
CC       lipid-linked oligosaccharides. {ECO:0000269|PubMed:15148656,
CC       ECO:0000269|PubMed:15945070}.
CC   -!- CATALYTIC ACTIVITY: Dolichyl beta-D-mannosyl phosphate + D-Man-
CC       alpha-(1->2)-D-Man-alpha-(1->2)-D-Man-alpha-(1->3)-(D-Man-alpha-
CC       (1->3)-D-Man-alpha-(1->6))-D-Man-beta-(1->4)-D-GlcNAc-beta-(1->4)-
CC       D-GlcNAc-diphosphodolichol = D-Man-alpha-(1->2)-D-Man-alpha-
CC       (1->2)-D-Man-alpha-(1->3)-(D-Man-alpha-(1->2)-D-Man-alpha-(1->3)-
CC       D-Man-alpha-(1->6))-D-Man-beta-(1->4)-D-GlcNAc-beta-(1->4)-D-
CC       GlcNAc-diphosphodolichol + dolichyl phosphate.
CC       {ECO:0000269|PubMed:15148656, ECO:0000269|PubMed:15945070}.
CC   -!- CATALYTIC ACTIVITY: Dolichyl beta-D-mannosyl phosphate + D-Man-
CC       alpha-(1->2)-D-Man-alpha-(1->2)-D-Man-alpha-(1->3)-(D-Man-alpha-
CC       (1->2)-D-Man-alpha-(1->3)-(D-Man-alpha-(1->6))-D-Man-alpha-
CC       (1->6))-D-Man-beta-(1->4)-D-GlcNAc-beta-(1->4)-D-GlcNAc-
CC       diphosphodolichol = D-Man-alpha-(1->2)-D-Man-alpha-(1->2)-D-Man-
CC       alpha-(1->3)-[D-Man-alpha-(1->2)-D-Man-alpha-(1->3)-(D-Man-alpha-
CC       (1->2)-D-Man-alpha-(1->6))-D-Man-alpha-(1->6)]-D-Man-beta-(1->4)-
CC       D-GlcNAc-beta-(1->4)-D-GlcNAc-diphosphodolichol + dolichyl
CC       phosphate. {ECO:0000269|PubMed:15148656,
CC       ECO:0000269|PubMed:15945070}.
CC   -!- PATHWAY: Protein modification; protein glycosylation.
CC       {ECO:0000269|PubMed:15148656, ECO:0000269|PubMed:15945070}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000305|PubMed:15148656}; Multi-pass membrane protein
CC       {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q9H6U8-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9H6U8-2; Sequence=VSP_015434;
CC       Name=3;
CC         IsoId=Q9H6U8-3; Sequence=VSP_015435;
CC       Name=4;
CC         IsoId=Q9H6U8-4; Sequence=VSP_015434, VSP_015435;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed; with highest levels in
CC       heart, liver and pancreas. {ECO:0000269|PubMed:12030331}.
CC   -!- DISEASE: Note=A chromosomal aberration involving ALG9 is found in
CC       a family with bipolar affective disorder. Translocation
CC       t(9;11)(p24;q23). However, common variations in ALG9 do not play a
CC       major role in predisposition to bipolar affective disorder.
CC       {ECO:0000269|PubMed:12030331}.
CC   -!- DISEASE: Congenital disorder of glycosylation 1L (CDG1L)
CC       [MIM:608776]: A form of congenital disorder of glycosylation, a
CC       multisystem disorder caused by a defect in glycoprotein
CC       biosynthesis and characterized by under-glycosylated serum
CC       glycoproteins. Congenital disorders of glycosylation result in a
CC       wide variety of clinical features, such as defects in the nervous
CC       system development, psychomotor retardation, dysmorphic features,
CC       hypotonia, coagulation disorders, and immunodeficiency. The broad
CC       spectrum of features reflects the critical role of N-glycoproteins
CC       during embryonic development, differentiation, and maintenance of
CC       cell functions. {ECO:0000269|PubMed:15148656,
CC       ECO:0000269|PubMed:15945070}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Gillessen-Kaesbach-Nishimura syndrome (GIKANIS)
CC       [MIM:263210]: A rare autosomal recessive syndrome characterized by
CC       severe skeletal dysplasia, facial dysmorphic features, polycystic
CC       kidney disease and other visceral malformations. It may be lethal
CC       in utero or early in life. The skeletal features uniformly
CC       comprise a round pelvis, mesomelic shortening of the upper limbs
CC       and defective ossification of the cervical spine.
CC       {ECO:0000269|PubMed:25966638}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the glycosyltransferase 22 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF395532; AAL25798.1; -; mRNA.
DR   EMBL; AF454937; AAP97696.1; -; mRNA.
DR   EMBL; AL136927; CAB66861.1; -; mRNA.
DR   EMBL; AK025498; BAB15154.1; -; mRNA.
DR   EMBL; AK172828; BAD18793.1; -; mRNA.
DR   EMBL; BC009255; AAH09255.1; -; mRNA.
DR   CCDS; CCDS41714.1; -. [Q9H6U8-4]
DR   CCDS; CCDS53709.1; -. [Q9H6U8-2]
DR   CCDS; CCDS73379.1; -. [Q9H6U8-1]
DR   CCDS; CCDS73380.1; -. [Q9H6U8-3]
DR   RefSeq; NP_001071158.1; NM_001077690.1. [Q9H6U8-1]
DR   RefSeq; NP_001071159.1; NM_001077691.1. [Q9H6U8-4]
DR   RefSeq; NP_001071160.1; NM_001077692.1. [Q9H6U8-2]
DR   RefSeq; NP_079016.2; NM_024740.2. [Q9H6U8-3]
DR   RefSeq; XP_016873808.1; XM_017018319.1. [Q9H6U8-4]
DR   RefSeq; XP_016873809.1; XM_017018320.1. [Q9H6U8-4]
DR   RefSeq; XP_016873810.1; XM_017018321.1. [Q9H6U8-2]
DR   RefSeq; XP_016873811.1; XM_017018322.1. [Q9H6U8-2]
DR   UniGene; Hs.745155; -.
DR   ProteinModelPortal; Q9H6U8; -.
DR   BioGrid; 122893; 33.
DR   IntAct; Q9H6U8; 6.
DR   MINT; MINT-3068633; -.
DR   STRING; 9606.ENSP00000435517; -.
DR   CAZy; GT22; Glycosyltransferase Family 22.
DR   iPTMnet; Q9H6U8; -.
DR   PhosphoSitePlus; Q9H6U8; -.
DR   BioMuta; ALG9; -.
DR   DMDM; 73921666; -.
DR   EPD; Q9H6U8; -.
DR   MaxQB; Q9H6U8; -.
DR   PaxDb; Q9H6U8; -.
DR   PeptideAtlas; Q9H6U8; -.
DR   PRIDE; Q9H6U8; -.
DR   DNASU; 79796; -.
DR   Ensembl; ENST00000398006; ENSP00000381090; ENSG00000086848. [Q9H6U8-2]
DR   Ensembl; ENST00000531154; ENSP00000435517; ENSG00000086848. [Q9H6U8-4]
DR   Ensembl; ENST00000614444; ENSP00000484200; ENSG00000086848. [Q9H6U8-1]
DR   Ensembl; ENST00000616540; ENSP00000482437; ENSG00000086848. [Q9H6U8-3]
DR   GeneID; 79796; -.
DR   KEGG; hsa:79796; -.
DR   UCSC; uc001ply.4; human. [Q9H6U8-1]
DR   CTD; 79796; -.
DR   DisGeNET; 79796; -.
DR   GeneCards; ALG9; -.
DR   GeneReviews; ALG9; -.
DR   HGNC; HGNC:15672; ALG9.
DR   HPA; HPA038575; -.
DR   MalaCards; ALG9; -.
DR   MIM; 263210; phenotype.
DR   MIM; 606941; gene.
DR   MIM; 608776; phenotype.
DR   neXtProt; NX_Q9H6U8; -.
DR   OpenTargets; ENSG00000086848; -.
DR   Orphanet; 79328; ALG9-CDG.
DR   PharmGKB; PA134887582; -.
DR   eggNOG; KOG2515; Eukaryota.
DR   eggNOG; ENOG410XP6D; LUCA.
DR   GeneTree; ENSGT00390000004731; -.
DR   HOVERGEN; HBG062906; -.
DR   InParanoid; Q9H6U8; -.
DR   KO; K03846; -.
DR   OrthoDB; EOG091G01ZZ; -.
DR   PhylomeDB; Q9H6U8; -.
DR   BRENDA; 2.4.1.259; 2681.
DR   BRENDA; 2.4.1.261; 2681.
DR   Reactome; R-HSA-446193; Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein.
DR   UniPathway; UPA00378; -.
DR   GeneWiki; ALG9; -.
DR   GenomeRNAi; 79796; -.
DR   PRO; PR:Q9H6U8; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000086848; -.
DR   CleanEx; HS_ALG9; -.
DR   ExpressionAtlas; Q9H6U8; baseline and differential.
DR   Genevisible; Q9H6U8; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IBA:GO_Central.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0000026; F:alpha-1,2-mannosyltransferase activity; TAS:Reactome.
DR   GO; GO:0052926; F:dol-P-Man:Man(6)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferase activity; IEA:UniProtKB-EC.
DR   GO; GO:0052918; F:dol-P-Man:Man(8)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferase activity; IEA:UniProtKB-EC.
DR   GO; GO:0000030; F:mannosyltransferase activity; IBA:GO_Central.
DR   GO; GO:0006488; P:dolichol-linked oligosaccharide biosynthetic process; TAS:Reactome.
DR   GO; GO:0006486; P:protein glycosylation; IEA:UniProtKB-UniPathway.
DR   InterPro; IPR005599; GPI_mannosylTrfase.
DR   PANTHER; PTHR22760; PTHR22760; 1.
DR   Pfam; PF03901; Glyco_transf_22; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Chromosomal rearrangement; Complete proteome;
KW   Congenital disorder of glycosylation; Disease mutation;
KW   Endoplasmic reticulum; Glycoprotein; Glycosyltransferase; Membrane;
KW   Polymorphism; Reference proteome; Transferase; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN         1    611       Alpha-1,2-mannosyltransferase ALG9.
FT                                /FTId=PRO_0000215787.
FT   TOPO_DOM      1    135       Lumenal. {ECO:0000255}.
FT   TRANSMEM    136    156       Helical. {ECO:0000255}.
FT   TOPO_DOM    157    171       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    172    192       Helical. {ECO:0000255}.
FT   TOPO_DOM    193    213       Lumenal. {ECO:0000255}.
FT   TRANSMEM    214    234       Helical. {ECO:0000255}.
FT   TOPO_DOM    235    249       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    250    270       Helical. {ECO:0000255}.
FT   TOPO_DOM    271    304       Lumenal. {ECO:0000255}.
FT   TRANSMEM    305    325       Helical. {ECO:0000255}.
FT   TOPO_DOM    326    342       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    343    363       Helical. {ECO:0000255}.
FT   TOPO_DOM    364    370       Lumenal. {ECO:0000255}.
FT   TRANSMEM    371    391       Helical. {ECO:0000255}.
FT   TOPO_DOM    392    405       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    406    426       Helical. {ECO:0000255}.
FT   TOPO_DOM    427    611       Lumenal. {ECO:0000255}.
FT   SITE        340    340       Breakpoint for translocation.
FT                                {ECO:0000269|PubMed:12030331}.
FT   CARBOHYD     77     77       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    593    593       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ       1    171       Missing (in isoform 2 and isoform 4).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|Ref.2}.
FT                                /FTId=VSP_015434.
FT   VAR_SEQ     391    391       Q -> QHSFLYFQ (in isoform 3 and isoform
FT                                4). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_015435.
FT   VARIANT     232    232       A -> P (in dbSNP:rs36111204).
FT                                /FTId=VAR_049221.
FT   VARIANT     255    255       S -> L (in dbSNP:rs17113312).
FT                                /FTId=VAR_049222.
FT   VARIANT     287    287       Y -> C (in CDG1L; impairs activity;
FT                                dbSNP:rs121908023).
FT                                {ECO:0000269|PubMed:15945070}.
FT                                /FTId=VAR_023410.
FT   VARIANT     289    289       V -> I (in dbSNP:rs10502151).
FT                                {ECO:0000269|PubMed:12030331,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15148656}.
FT                                /FTId=VAR_023411.
FT   VARIANT     506    506       P -> L (in dbSNP:rs185149177).
FT                                {ECO:0000269|PubMed:12030331}.
FT                                /FTId=VAR_023412.
FT   VARIANT     523    523       E -> K (in CDG1L; impairs activity;
FT                                dbSNP:rs121908022).
FT                                {ECO:0000269|PubMed:15148656}.
FT                                /FTId=VAR_023413.
FT   VARIANT     528    528       I -> S (in dbSNP:rs12575909).
FT                                /FTId=VAR_049223.
FT   CONFLICT    309    309       N -> K (in Ref. 1 and 2). {ECO:0000305}.
SQ   SEQUENCE   611 AA;  69863 MW;  51EC72DDBD866713 CRC64;
     MASRGARQRL KGSGASSGDT APAADKLREL LGSREAGGAE HRTELSGNKA GQVWAPEGST
     AFKCLLSARL CAALLSNISD CDETFNYWEP THYLIYGEGF QTWEYSPAYA IRSYAYLLLH
     AWPAAFHARI LQTNKILVFY FLRCLLAFVS CICELYFYKA VCKKFGLHVS RMMLAFLVLS
     TGMFCSSSAF LPSSFCMYTT LIAMTGWYMD KTSIAVLGVA AGAILGWPFS AALGLPIAFD
     LLVMKHRWKS FFHWSLMALI LFLVPVVVID SYYYGKLVIA PLNIVLYNVF TPHGPDLYGT
     EPWYFYLING FLNFNVAFAL ALLVLPLTSL MEYLLQRFHV QNLGHPYWLT LAPMYIWFII
     FFIQPHKEER FLFPVYPLIC LCGAVALSAL QKCYHFVFQR YRLEHYTVTS NWLALGTVFL
     FGLLSFSRSV ALFRGYHGPL DLYPEFYRIA TDPTIHTVPE GRPVNVCVGK EWYRFPSSFL
     LPDNWQLQFI PSEFRGQLPK PFAEGPLATR IVPTDMNDQN LEEPSRYIDI SKCHYLVDLD
     TMRETPREPK YSSNKEEWIS LAYRPFLDAS RSSKLLRAFY VPFLSDQYTV YVNYTILKPR
     KAKQIRKKSG G
//
